Abstract

To investigate the significance attributed to the utilization of sintilimab in conjunction with bevacizumab for patients suffering from advanced hepatocellular carcinoma. During the period spanning from March 2020 to March 2023, our center enrolled a 104 individuals with advanced hepatocellular carcinoma, who were then allocated into either the observation group (treated with sintilimab and bevacizumab) or the control group (treated with sintilimab). Safety was the primary outcome of this study, evaluated by monitoring and recording adverse events. The QLQ-C30 questionnaire was utilized to evaluate healthrelated life quality and hepatocellular carcinoma-specific symptoms, and overall survival rate was the secondary outcome. The two groups exhibited similar baseline characteristics, without any significant differences (p>0.05). The two groups did not significantly differ in terms of the incidence of each adverse event; however, the observation group had a significantly higher overall incidence rate of adverse events than the control group (p<0.05). The QLQ-C30 scores of both groups showed significant improvement compared to baseline, with more significant improvements observed in the observation group in terms of overall health status, physical functioning and emotional functioning (p<0.05). In terms of overall survival rate, the observation group outperformed the control group significantly. In conclusion, when treating individuals with advanced hepatocellular carcinoma, the joined administration of sintilimab and bevacizumab may result in a higher frequency of adverse events. Nevertheless, this treatment approach offers the benefits of improved overall survival rate and enhanced quality of life, underscoring its considerable clinical value and suitability for promotion.